ASX - Delayed Quote AUD

InhaleRx Limited (IRX.AX)

Compare
0.0250
0.0000
(0.00%)
At close: April 1 at 2:05:10 PM GMT+11
Loading Chart for IRX.AX
  • Previous Close 0.0250
  • Open 0.0250
  • Bid 0.0210 x --
  • Ask 0.0230 x --
  • Day's Range 0.0250 - 0.0250
  • 52 Week Range 0.0200 - 0.0500
  • Volume 138,978
  • Avg. Volume 50,405
  • Market Cap (intraday) 5.336M
  • Beta (5Y Monthly) -0.22
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date Feb 26, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

InhaleRx Limited engages in the developing and commercializing of medical drug delivery systems in Australia. It also develops inhaled drug formulations. The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021. InhaleRx Limited was incorporated in 2016 and is based in Melbourne, Australia.

inhalerx.com.au

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IRX.AX

View More

Performance Overview: IRX.AX

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

IRX.AX
28.57%
S&P/ASX 200 [XJO] (^AXJO)
6.02%

1-Year Return

IRX.AX
37.50%
S&P/ASX 200 [XJO] (^AXJO)
1.36%

3-Year Return

IRX.AX
79.17%
S&P/ASX 200 [XJO] (^AXJO)
2.05%

5-Year Return

IRX.AX
51.41%
S&P/ASX 200 [XJO] (^AXJO)
51.31%

Compare To: IRX.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IRX.AX

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    5.34M

  • Enterprise Value

    5.18M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -69.85%

  • Return on Equity (ttm)

    -402.12%

  • Revenue (ttm)

    401.81k

  • Net Income Avi to Common (ttm)

    -1.21M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    194.91k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -95.17k

Research Analysis: IRX.AX

View More

Company Insights: IRX.AX

Research Reports: IRX.AX

View More

People Also Watch